Empfohlene Nahrungsergänzungen und deren Mechanismen bei Lipödem

Literaturverzeichnis

1. 1
   Herbst Karen L (2012). Rare adipose disorders (RADs) masquerading as obesity.. Acta pharmacologica Sinica. PubMed.https://doi.org/10.1038/aps.2011.153

   ▼Zusammenfassung

   Rare adipose disorders (RADs) including multiple symmetric lipomatosis (MSL), lipedema and Dercum's disease (DD) may be misdiagnosed as obesity. Lifestyle changes, such as reduced caloric intake and increased physical activity are standard care for obesity. Although lifestyle changes and bariatric surgery work effectively for the obesity component of RADs, these treatments do not routinely reduce the abnormal subcutaneous adipose tissue (SAT) of RADs. RAD SAT likely results from the growth of a brown stem cell population with secondary lymphatic dysfunction in MSL, or by primary vascular and lymphatic dysfunction in lipedema and DD. People with RADs do not lose SAT from caloric limitation and increased energy expenditure alone. In order to improve recognition of RADs apart from obesity, the diagnostic criteria, histology and pathophysiology of RADs are presented and contrasted to familial partial lipodystrophies, acquired partial lipodystrophies and obesity with which they may be confused. Treatment recommendations focus on evidence-based data and include lymphatic decongestive therapy, medications and supplements that support loss of RAD SAT. Associated RAD conditions including depression, anxiety and pain will improve as healthcare providers learn to identify and adopt alternative treatment regimens for the abnormal SAT component of RADs. Effective dietary and exercise regimens are needed in RAD populations to improve quality of life and construct advanced treatment regimens for future generations.
2. 2
   Bonetti Gabriele, Herbst Karen L, Dhuli Kristjana, Kiani Aysha Karim, Michelini Serena, Michelini Silvia, Ceccarini Maria Rachele, Michelini Sandro, Ricci Maurizio, Cestari Marina, Codini Michela, Beccari Tommaso, Bellinato Francesco, Gisondi Paolo, Bertelli Matteo (2022). Dietary supplements for lipedema.. Journal of preventive medicine and hygiene. PubMed.https://doi.org/10.15167/2421-4248/jpmh2022.63.2S3.2758

   ▼Zusammenfassung

   Lipedema is a chronic disease that mostly manifests in females as the abnormal distribution of subcutaneous adipose connective tissue, usually coupled with bruising, pain, and edema. Lipedema molecular pathophysiology is currently not clear, but several studies suggest that genetics and hormonal imbalance participate in lipedema pathogenesis. Women with lipedema present in some cases with elevated body mass index, and the appearance of obesity in addition to lipedema, where the obesity can cause serious health issues as in lipedema-free individuals with obesity, such as diabetes and cardiovascular disorders. Unlike obesity, lipedema tissue does not respond well to diet or physical exercise alone. Therefore, in this review we discuss the effect of various dietary supplements that, along with diet and physical exercise, cause fat burning and weight loss, and which could potentially be important in the treatment of lipedema. Indeed, an effective fat burner should convert stored fats into energy, mobilize and break down triglycerides in adipocytes, boost metabolism and inhibit lipogenesis. Common ingredients of fat burning supplements are green tea, caffeine, chromium, carnitine, and conjugated linoleic acid. The use of fat burners could act synergistically with a healthy diet and physical exercise for decreasing adipose tissue deposition in patients with lipedema and resolve related health issues. The effects of fat burners in human studies are sometimes contradictory, and further studies should test their effectiveness in treating lipedema.
3. 3
   Atabilen Pınar Büşra, Çelik Menşure Nur, Altıntaş Başar Hilal Betül, Ağagündüz Duygu, Karaca Oya Berkay (2025). Current Evidence-Based Clinical Nutritional Approaches in Lipedema: A Scoping Review.. Nutrition reviews. PubMed.https://doi.org/10.1093/nutrit/nuaf203

   ▼Zusammenfassung

   Lipedema, a chronic condition primarily affecting women, is characterized by abnormal subcutaneous fat accumulation and swelling in the extremities (while sparing the hands, feet, and trunk). This disease is associated with genetic predisposition, hormonal imbalances, impaired lymphatic function, and vascular dysfunction. Lipedema does not directly cause weight gain, but excess weight can worsen symptoms and accelerate disease progression. Bariatric surgery is considered a treatment option for body weight management and reduction of subcutaneous fat; however, reported studies have indicated that this treatment cannot reduce localized fat accumulation or fat cell hypertrophy or alleviate pain symptoms. Although no proven dietary treatment currently exists, nutrition plays a key role in managing lipedema. Certain dietary approaches such as ketogenic, low-carbohydrate, and modified Mediterranean diets have been explored for weight management and inflammation reduction in lipedema, with studies showing positive effects on body composition and pain. However, according to the current literature no evidence-based nutritional treatments or nutritional supplements are effective in this patient group. Nutritional therapy in lipedema is complicated by frequent comorbidities; therefore, precision nutritional therapy should be planned by evaluating the causes and consequences of the disease. In this review, we evaluated reported studies of current evidence-based clinical nutritional approaches to lipedema treatment.
4. 4
   Bonetti Gabriele, Herbst Karen L, Donato Kevin, Dhuli Kristjana, Kiani Aysha Karim, Aquilanti Barbara, Velluti Valeria, Matera Giuseppina, Iaconelli Amerigo, Bertelli Matteo (2022). Dietary supplements for obesity.. Journal of preventive medicine and hygiene. PubMed.https://doi.org/10.15167/2421-4248/jpmh2022.63.2S3.2757

   ▼Zusammenfassung

   Obesity and associated complications including diabetes, cardiometabolic dysfunction, disability, malignancy and premature mortality are considered epidemic. Research on obesity is therefore of worldwide importance. The development of obesity is a multifactorial phenomenon with contributions from biological, behavioral, genetic and environmental factors. Obesity and its associated issues require various lifestyle modifications and treatment options such medication, exercise, diet, surgery, pharmacological therapy and dietary supplements. Dietary supplements are considered an attractive alternative to traditional therapy due to their low toxicity profile and their accessibility to the general population. Dietary supplements may include one or more dietary ingredients. In this narrative review, we analyze the effects on obesity and obesity-related issues of various natural components. For example, there are a myriad of supplements that have been used as dietary supplements for weight loss such as minerals, vitamins, amino acids, metabolites, herbs, and plant extracts. This narrative review aims to present the benefits and side-effects of several ingredients of dietary supplements for weight loss and treatment of obesity. In particular, the mechanism of action, results of clinical trials, and possible side effects will be presented for the following ingredients: β-Glucans, bitter orange, calcium, vitamin D, chitosan, chromium, cocoa, coleus forskohlii, conjugate linoleic acid, ephedra sinica, fucoxanthin, garcinia cambogia, glucomannan, green coffee, green tea, guar gum, raspberry, hoodia gordonii, irvingia gabonensis, phenylpropylamine, pyruvate, white kidney bean.
5. 5
   Kreidel Yannic, Himmelreich Viktoria, Klaus Anna-Maria, Franke Gabriele Helga, Hinz Andreas, Brähler Elmar, Petrowski Katja, Zenger Markus (2025). [Health-related quality of life and psychological abnormalities in patients with lipedema compared to healthy and chronically ill populations].. Psychotherapie, Psychosomatik, medizinische Psychologie. PubMed.https://doi.org/10.1055/a-2541-7595

   ▼Zusammenfassung

   Lipedema is a chronical progressive disease mostly found in women, characterized by an unproportional increase of fat in the limbs and pain. So far mental perspectives are not acceptably resolved. This study examines patients' aspects in health-related quality of life.733 women with lipedema were asked to answer the questionnaires SF-36, Mini-SCL, EFK, DKB-35 and RSES which were compared with normative data. Additional questions for continuative analysis were appended.Depending on the comparison sample, statistical calculation showed significant differences of means in all collected aspects of health-related quality of life. Affected people reported consistently more impairment. Investigations in coping showed that 'depressive processing' is used most frequently. Furthermore, there were significant saliences in SF-36 scales regarding to the stadium and the use of conservative therapies. Analyses of answers to additional questions showed that most patients feel insufficient understood by fellow men. Also, nearly the half feels inadequately informed about the disease.The outcome exposes clear restrictions in quality of life in patients with lipedema. Previous publications can be confirmed and supplemented. However, the study design of an open online survey makes distortions (e. g. selection of highly informed patients) within the sample possible.The resulting need of psychological interventions is obvious. In addition, enlightenment and sensitization in science and public are important to reduce stigmatization, to relieve patients' everyday life and increase the quality of life.
6. 6
   Listed No Authors (2024). Expression of Concern.. European review for medical and pharmacological sciences. PubMed.https://doi.org/10.26355/eurrev_202401_35160

   ▼Zusammenfassung

   The Editor in Chief and the Publisher are issuing an expression of concern to alert readers to the fact that the Special Issue titled "Omics sciences in the personalization of diagnosis and therapy" and, in particular, the following articles: ·      J. Kaftalli, K. Donato, G. Bonetti, K. Dhuli, A. Macchia, P.E. Maltese, K. Louise Herbst, S. Michelini, P. Chiurazzi, M. Hill, S. Michelini, S. Michelini, G. Marceddu, A. Bernini, M. Bertelli. Aldo-keto reductase 1C2 (AKR1C2) as the second gene associated to non-syndromic primary lipedema: investigating activating mutation or overexpression as causative factors. Eur Rev Med Pharmacol Sci 2023; 27 (6 Suppl): 127-136. DOI: 10.26355/eurrev_202312_34697-PMID: 38112953. ·      M.C. Medori, K. Donato, L. Stuppia, T. Beccari, M. Dundar, R.S. Marks, S. Michelini, E. Borghetti, C. Zuccato, L. Seppilli, H. Elsangak, G. Sozanski, D. Malacarne, M. Bertelli. Achievement of sustainable development goals through the Mediterranean diet. Eur Rev Med Pharmacol Sci 2023; 27 (6 Suppl): 89-99. DOI: 10.26355/eurrev_202312_34693-PMID: 38112950. ·      K. Donato, M.C. Medori, A. Macchia, S. Cecchin, M.R. Ceccarini, T. Beccari, V. Gatta, L. Stuppia, V. Benfatti, L. Dalla Ragione, P. Chiurazzi C. Micheletti, K. Dhuli, G. Madeo, G. Bonetti, G. Marceddu, M. Bertelli. Genetic variants identified in novel candidate genes for anorexia nervosa and analysis of molecular pathways for diagnostic applications. Eur Rev Med Pharmacol Sci 2023; 27 (6 Suppl): 77-88. DOI: 10.26355/eurrev_202312_34692-PMID: 38112957. ·      K. Donato, K. Dhuli, A. Macchia, M.C. Medori, C. Micheletti, G. Bonetti, M.R. Ceccarini, T. Beccari, P. Chiurazzi, S. Cristoni, V. Benfatti, L. Dalla Ragione, M. Bertelli. Metabolomic profiling of amino acid alterations in anorexia nervosa: implications for appetite regulation and therapeutic strategies. Eur Rev Med Pharmacol Sci 2023; 27 (6 Suppl): 64-76. DOI: 10.26355/eurrev_202312_34691-PMID: 38112949. ·      M.R. Ceccarini, M.C. Medori, K. Dhuli, S. Tezzele, G. Bonetti, C. Micheletti, P.E. Maltese, S. Cecchin, K. Donato, L. Colombo, L. Rossetti, G. Staurenghi, A.P. Salvetti, M. Oldani, L. Ziccardi, D. Marangoni, G. Iarossi, B. Falsini, G. Placidi, F. D'Esposito, F. Viola, M. Nassisi, G. Leone, L. Cimino, L. De Simone, V. Mastrofilippo, T. Beccari, M. Bertelli. Autoantibodies detection in patients affected by autoimmune retinopathies. Eur Rev Med Pharmacol Sci 2023; 27 (6 Suppl): 57-63. DOI: 10.26355/eurrev_202312_34690-PMID: 38112948. ·      E. Kalluçi, E. Noka, K. Bani, X. Dhamo, I. Alimehmeti, K. Dhuli, G. Madeo, C. Micheletti, G. Bonetti, C. Zuccato, E. Borghetti, G. Marceddu, M. Bertelli. Correlation between COVID-19 and air pollution: the effects of PM2.5 and PM10 on COVID-19 outcomes. Eur Rev Med Pharmacol Sci 2023; 27 (6 Suppl): 39-47. DOI: 10.26355/eurrev_202312_34688-PMID: 38112947. ·      K. Dhuli, C. Micheletti, M.C. Medori, G. Madeo, G. Bonetti, K. Donato, F. Gaffuri, G.M. Tartaglia, S. Michelini, A. Fiorentino, D. Cesarz, S.T. Connelly, N. Capodicasa, M. Bertelli. The potential preventive role of a dietary supplement containing hydroxytyrosol in COVID-19: a multi-center study. Eur Rev Med Pharmacol Sci 2023; 27 (6 Suppl): 33-38. DOI: 10.26355/eurrev_202312_34687-PMID: 38112946. ·      K. Dhuli, M.C. Medori, C. Micheletti, K. Donato, F. Fioretti, A. Calzoni, A. Praderio, M.G. De Angelis, G. Arabia, S. Cristoni, S. Nodari, M. Bertelli. Presence of viral spike protein and vaccinal spike protein in the blood serum of patients with long-COVID syndrome. Eur Rev Med Pharmacol Sci 2023; 27 (6 Suppl): 13-19. DOI: 10.26355/eurrev_202312_34685-PMID: 38112944. are being reviewed again after publication by an independent Editor and a new group of reviewers due to concerns raised by readers on PubPeer regarding an undisclosed authors' conflict of interest and methodological issues of some articles. Further updates will be provided once the investigation is completed. The authors have been notified about this expression of concern.
7. 7
   Zetzmann Katharina, Ludolph Ingo, Horch Raymund E, Boos Anja Miriam (2018). [Imaging for treatment planning in lipo-and lymphedema].. Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V.... PubMed.https://doi.org/10.1055/a-0739-7911

   ▼Zusammenfassung

   Lipoedema is a progressive disease, which predominantly affects women. It is characterised by circumferential growth, with increase in fat tissue of the extremities, and can lead to oedema. In contrast, the lymphoedema is defined by a specific lymphatic drainage disorder and can lead to fibrosis of the surrounding connective tissue. While lipoedema is diagnosed through clinical symptoms and diagnostic imaging can usually only be used to rule out comorbidities, lymphatic drainage disorder can be visualised using imaging methods. Ultrasound is a basis diagnostic tool to show retained interstitial fluid in lip- and lymphoedema. Lymphoscintigraphy is considered to be the gold standard to demonstrate a lymphatic drainage disorder, which can be combined with computed tomography. Indocyanine green(ICG) lymphography is a dynamic imaging tool, which is of increasing significance due to its possible intraoperative use. Magnetic resonance imaging (MRI) lymphography has the ability to visualise a lymphoedema and a lymphatic drainage disorder in three dimensions and is therefore considered to be a meaningful supplement. Therapy of lip- and lymphoedema should always be based on a combination of conservative and surgical strategies. While liposuction and other resection procedures can lead to symptom relief in lipedoema or advanced lymphoedema, newer reconstructive procedures such as lymph node transplantation or lymphovenous anastomoses are modern techniques to treat lymphoedema. A long lasting volume reduction can be achieved by creating new lymphatic pathways leading to improved quality of life and reduced symptoms.